A Multimodal iPSC Platform Advances Cystic Fibrosis Drug Testing

Study Background and Research Question

Cystic fibrosis (CF) is a severe monogenic disorder caused by mutations in the CFTR gene, leading to defective chloride ion transport and progressive multi-organ disease, especially impacting the lungs. Although the advent of CFTR modulator therapies has improved outcomes for the majority of patients, a notable subset—particularly those with rare or class 1 CFTR variants—remain without effective targeted treatments. Traditional preclinical models, including primary human bronchial epithelial cells (HBECs) and heterologous cell lines, have been instrumental in modulator development but face limitations in scalability, patient representation, and technical accessibility. This context frames the central research question: can induced pluripotent stem cell (iPSC)-derived airway epithelial cells provide a reproducible, patient-specific platform for functional assessment and drug testing across diverse CFTR genotypes?

Key Innovation from the Reference Study

The reference study (Berical et al., 2022) presents a robust, multimodal iPSC-based system for modeling CF airway disease. The authors generated a diverse panel of airway epithelial cells derived from iPSCs reprogrammed from individuals carrying common and rare CFTR mutations. Critically, they adapted two established functional assays—3D spheroid swelling and planar mucociliary epithelial cultures—for use with these iPSC-derived cells. This dual approach captures both the functional heterogeneity of CFTR variants and the cellular complexity of the airway epithelium. Their innovation enables genotype-driven analysis of baseline CFTR function and pharmacological response, addressing unmet needs in preclinical modeling of rare CFTR mutations.

Methods and Experimental Design Insights

The study's experimental design integrated several methodological advances:

• iPSC Generation and Differentiation: iPSCs were created from patient samples representing three distinct classes of CFTR dysfunction (affecting protein quantity, trafficking, gating, and conductance). Differentiation protocols were optimized to yield airway epithelial cells capable of forming both 3D spheroids and planar, polarized cultures.
• Multi-Assay Functional Characterization: Two complementary assays were employed: (1) a 3D spheroid system measuring forskolin-induced swelling as a surrogate for cAMP-activated CFTR function, and (2) planar mucociliary cultures suitable for Ussing chamber-based electrophysiology, assessing ion channel activity in a physiologically relevant context.
• Drug Response Profiling: The platform allowed for systematic evaluation of baseline and modulator-induced CFTR activity across different genotypes, enabling assessment of both common and rare mutation responses to candidate therapies.

By adapting these functional assays for iPSC-derived airway cells, the authors ensured compatibility with existing standards in CF research while markedly expanding the scope for personalized and high-throughput drug testing.

Protocol Parameters

• iPSC Differentiation: Standardized protocols for directed airway lineage differentiation, with careful monitoring of cell marker expression to confirm epithelial identity.
• 3D Spheroid Assay: Forskolin treatment (typically 5–10 μM) applied to mature spheroids to induce swelling, measured over 1–2 hours to assess CFTR-mediated fluid transport.
• Planar Culture Electrophysiology: Air-liquid interface (ALI) cultures matured for 2–4 weeks; Ussing chamber analysis performed using selective pharmacological activation and inhibition to isolate CFTR-specific currents.
• CFTR Modulator Testing: Acute and/or chronic exposure to clinically relevant modulators (e.g., VX-770, VX-809), with matched vehicle controls.

Core Findings and Why They Matter

The study demonstrated several impactful findings:

• iPSC-derived airway epithelial cells recapitulate key morphological and functional characteristics of primary airway cells, including ciliation and mucociliary differentiation.
• Both 3D and planar assays revealed genotype-specific differences in baseline CFTR function and in responses to CFTR modulators, mirroring clinical heterogeneity observed among patients.
• The multimodal platform successfully modeled rare CFTR variants, for which clinical trial data and primary cell resources are often lacking, providing a critical tool for therapeutic development in underserved patient groups.

These results highlight the potential for iPSC-derived airway models to bridge gaps in the current drug discovery pipeline, particularly for rare or previously uncharacterized CFTR mutations. The approach enables scalable, reproducible, and patient-specific functional studies that can inform both preclinical drug selection and future precision medicine strategies. According to the reference study, this platform could accelerate the evaluation of new therapies targeting the approximately 10% of CF patients not currently benefitting from CFTR modulators.

Comparison with Existing Internal Articles

The internal article "iPSC Models Advance Cystic Fibrosis Drug Testing and Stratification" provides an accessible overview of similar iPSC-based strategies, emphasizing the scalability and genotype-specific insights afforded by these models. Both sources converge on the value of patient-derived, pluripotent platforms in expanding the reach of preclinical drug testing. However, the current reference study distinguishes itself by its dual-assay approach—integrating both 3D spheroid and planar cultures—which more comprehensively recapitulates in vivo epithelial function and enables nuanced pharmacological profiling.

With regard to protein analysis workflows, articles such as "Native Protein Gel Electrophoresis: Functional Proteomics with the K4142 Kit" and "Optimizing Native Protein Gel Electrophoresis for Acidic Proteins" discuss the application of native PAGE systems in preserving protein structure and activity during electrophoretic separation. While these articles focus on biochemical assay optimization, their relevance increases when considering the need for functional protein validation in emerging stem cell-derived platforms, such as those described in the CF iPSC study.

Limitations and Transferability

While the iPSC-derived airway model addresses many limitations of traditional cell sources, several challenges remain. Differentiation protocols can yield variable efficiencies, and subtle differences in maturation or cell composition may affect functional readouts. The model’s ability to fully recapitulate the complex in vivo airway environment, including immune and stromal interactions, remains an area for further development. Additionally, while the platform supports high-throughput and genotype-specific studies, technical requirements for iPSC culture and differentiation may limit accessibility for some laboratories.

Importantly, the transferability of findings from iPSC-derived models to clinical outcomes, while promising, requires ongoing validation. The platform’s predictive value for drug efficacy, particularly for rare CFTR variants, will need to be continually benchmarked against primary cell and clinical data as new therapies emerge.

Research Support Resources

For researchers looking to implement similar workflows in protein analysis, the Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit (PI ≤ 7.0) (SKU K4142) from APExBIO provides a convenient system for native protein gel electrophoresis, particularly suited for the separation and analysis of acidic proteins. This kit facilitates protein purification and identification while preserving native structure and biological activity, supporting rigorous functional assays needed in stem cell-based disease modeling. Integration of such tools can enhance the reliability of protein-level investigations alongside advanced cell-based assays.